JACOBIO-B (01167) has received a $100 million upfront payment under the license and collaboration agreement with AstraZeneca for the KRAS inhibitor JAB-23E73.

date
08:02 30/03/2026
avatar
GMT Eight
Jiakesi-B (01167) announced that its affiliate company Beijing Jiakesi New Drug Development Co., Ltd. (Beijing Jiakesi), a non-wholly owned subsidiary of the Group, has entered into a license and cooperation agreement with AstraZeneca AB. The Group's subsidiary Beijing Jiakesi has received a $100 million upfront payment from AstraZeneca for the license and cooperation agreement. The receipt of this upfront payment has further bolstered the Group's cash reserves and will provide support for the advancement of the Group's innovative oncology therapy pipeline research and development in the future.
JACOBIO-B (01167) announced that Beijing Jiake New Drug Development Co., Ltd. (Beijing Jiake, a non-wholly owned subsidiary of the group) has entered into a licensing and collaboration agreement with AstraZeneca AB. The subsidiary Beijing Jiake has received a $100 million upfront payment from AstraZeneca for the licensing and collaboration agreement. The receipt of this upfront payment has further strengthened the group's cash reserves and will support the advancement of the group's innovative pipeline for cancer therapy research and development.